Please join IPI on Thursday, June 4th for a special policy discussion on the Zoom platform with Amity Shlaes.

Compulsory licensing deters innovators from investing in drug discovery. It won’t reduce what patients pay.

Important legislation has been proposed that would encourage medical and pharmaceutical manufacturing to relocate to the U.S. by providing potent tax incentives instead of threats of government force.

Americans are the world’s top users of generics, but not of biosimilars. State and local governments should encourage a wider uptake for their own employees as an important start—and a much-needed cost savings. 

In America, where economic freedom and entrepreneurship can still fuel even the biggest of dreams, free enterprise is taking us into space.

American taxpayers are getting a safer, more advanced and much less expensive manned space program. And the key is the private sector.